FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | |||
|
||||
Senior Member
|
PLoS One.
Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. Gröger A, Kolb R, Schäfer R, Klose U. OBJECTIVES: Metabolic changes in the substantia nigra of patients with Parkinson's disease were previously investigated in different molecular-pathological examinations. The aim of our study was the in vivo measurement of these alterations using three-dimensional magnetic resonance spectroscopic imaging. METHODS: 21 patients with Parkinson's disease and 24 controls were examined using magnetic resonance spectroscopic imaging at 3 Tesla. The spectra of rostral and caudal substantia nigra regions were analyzed using LCModel. For spectral fitting, an adjusted basis data set with pathology-specific metabolites and macromolecules was used to better reproduce the in vivo spectra. To assess differences between both groups more accurately, especially in metabolites at lower concentrations, group-averaged spectra were evaluated in addition to the analysis of individual data. RESULTS: We found significantly decreased N-acetylaspartate, choline, creatine, myo-inositol, glutathione and dopamine concentrations in patients with Parkinson's disease compared to controls, whereas glutamine+glutamate, γ-aminobutyric acid, and homovanillic acid were slightly increased. According to anatomical features, clear differences in the biochemical profiles were found between rostral and caudal substantia nigra voxels in both groups. CONCLUSIONS: Reduced N-acetylaspartate and dopamine concentrations result from progressive degeneration of dopamine-producing neurons within the substantia nigra pars compacta. Decreased creatine levels can be interpreted as impaired energy metabolism due to mitochondrial dysfunction. Lower glutathione concentrations might be a cause or consequence of oxidative stress. Furthermore, slightly increased glutamine+glutamate and γ-aminobutyric acid levels are expected based on post mortem data in Parkinson's disease. To the best of our knowledge, this is the first non-invasive confirmation of these metabolic changes. PMID: 24416192 [PubMed - in process] PMCID: PMC3885536 Free PMC Article
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
![]() |
![]() |
"Thanks for this!" says: | anagirl (01-19-2014), girija (01-19-2014), lab rat (01-19-2014), lindylanka (01-21-2014), mrsD (01-19-2014), reverett123 (01-20-2014), soccertese (01-19-2014), Tupelo3 (01-19-2014) |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
Magnetic resonance neurography (MRN) Has anyone gotten one? | Peripheral Neuropathy | |||
magnetic resonance (MRI) causes Small Fibers Neuropathies? | Peripheral Neuropathy | |||
Magnetic Resonance and neuropathic pain | Peripheral Neuropathy | |||
Magnetic Resonance Angiography | Reflex Sympathetic Dystrophy (RSD and CRPS) |